Cohort profile: Antiretroviral Therapy Cohort Collaboration (ART-CC)

Margaret T May¹, Suzanne M Ingle², Dominique Costagliola², Amy C Justice³, Frank de Wolf², Matthias Cavassini², Antonella D'Arminio Monforte², Jordi Casabona², Robert S Hogg³, Amanda Mocroft², Fiona C Lampe², François Dabis², Gerd Fätkenheuer², Timothy R Sterling², Julia del Amo², M John Gill², Heidi M Crane², Michael S Saag², Jodie Guest², Hans-Reinhard Brodt², Jonathan A C Sterne²; Antiretroviral Cohort Collaboration

Collaborators, Affiliations

Collaborators

Affiliations

¹ School of Social and Community Medicine, University of Bristol, Bristol, UK, UPMC Univ Paris 06, UMR_S 943, F-75013, Paris, France; INSERM, UMR_S 943, F-75013, Paris, France; AP-HP, Hôpital Pitié-Salpétrière, Service des maladies infectieuses et tropicales, F-75013, Paris, France, Yale University School of Medicine, New Haven, CT, USA, VA Connecticut Healthcare System, West Haven, CT, USA, Academisch Medisch Centrum bij de Universiteit van Amsterdam, Amsterdam, The Netherlands, University Hospital Lausanne, Lausanne, Switzerland, Clinic of Infectious Diseases & Tropical Medicine, San Paolo Hospital, University of Milan, Italy, Centre d'Estudis Epidemiològics sobre ITS/VIH/SIDA de Catalunya, Badalona, Spain, Division of Epidemiology and Population Health, British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada, Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada, Research Department of Infection and Population Health, UCL Medical School, London, UK, INSERM U.897, ISPED, Université Bordeaux, Bordeaux, France, Department of Internal Medicine University of Cologne, DE, Vanderbilt University School of Medicine, Nashville, TN, USA, National Epidemiology Center. Carlos III Health Institute, Madrid, Spain, Division of Infectious Diseases, University of Calgary, Calgary, Canada, University of Washington School of Medicine, Seattle, WA, USA, Division of Infectious Disease, Department of Medicine, University of Alabama, Birmingham, USA, HIV Atlanta VA Cohort Study (HAVACS), Atlanta Veterans Affairs Medical Center, Decatur, GA, USA and Johann Wolfgang Goethe-Universität, HIVCENTER, Frankfurt, Germany m.t.may@bristol.ac.uk.
² School of Social and Community Medicine, University of Bristol, Bristol, UK, UPMC Univ Paris 06, UMR_S 943, F-75013, Paris, France; INSERM, UMR_S 943, F-75013, Paris, France; AP-HP, Hôpital Pitié-Salpétrière, Service des maladies infectieuses et tropicales, F-75013, Paris, France, Yale University School of Medicine, New Haven, CT, USA, VA Connecticut Healthcare System, West Haven, CT, USA, Academisch Medisch Centrum bij de Universiteit van Amsterdam, Amsterdam, The Netherlands, University Hospital Lausanne, Lausanne, Switzerland, Clinic of Infectious Diseases & Tropical Medicine, San Paolo Hospital, University of Milan, Italy, Centre d'Estudis Epidemiològics sobre ITS/VIH/SIDA de Catalunya, Badalona, Spain, Division of Epidemiology and Population Health, British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada, Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada, Research Department of Infection and Population Health, UCL Medical School, London, UK, INSERM U.897, ISPED, Université Bordeaux, Bordeaux, France, Department of Internal Medicine University of Cologne, DE, Vanderbilt University School of Medicine, Nashville, TN, USA, National Epidemiology Center. Carlos III Health Institute, Madrid, Spain, Division of Infectious Diseases, University of Calgary, Calgary, Canada, University of Washington School of Medicine, Seattle, WA, USA, Division of Infectious Disease, Department of Medicine, University of Alabama, Birmingham, USA, HIV Atlanta VA Cohort Study (HAVACS), Atlanta Veterans Affairs Medical Center, Decatur, GA, USA and Johann Wolfgang Goethe-Universität, HIVCENTER, Frankfurt, Germany.
³ School of Social and Community Medicine, University of Bristol, Bristol, UK, UPMC Univ Paris 06, UMR_S 943, F-75013, Paris, France; INSERM, UMR_S 943, F-75013, Paris, France; AP-HP, Hôpital Pitié-Salpétrière, Service des maladies infectieuses et tropicales, F-75013, Paris, France, Yale University School of Medicine, New Haven, CT, USA, VA Connecticut Healthcare System, West Haven, CT, USA, Academisch Medisch Centrum bij de Universiteit van Amsterdam, Amsterdam, The Netherlands, University Hospital Lausanne, Lausanne, Switzerland, Clinic of Infectious Diseases & Tropical Medicine, San Paolo Hospital, University of Milan, Italy, Centre d'Estudis Epidemiològics sobre ITS/VIH/SIDA de Catalunya, Badalona, Spain, Division of Epidemiology and Population Health, British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada, Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada, Research Department of Infection and Population Health, UCL Medical School, London, UK, INSERM U.897, ISPED, Université Bordeaux, Bordeaux, France, Department of Internal Medicine University of Cologne, DE, Vanderbilt University School of Medicine, Nashville, TN, USA, National Epidemiology Center. Carlos III Health Institute, Madrid, Spain, Division of Infectious Diseases, University of Calgary, Calgary, Canada, University of Washington School of Medicine, Seattle, WA, USA, Division of Infectious Disease, Department of Medicine, University of Alabama, Birmingham, USA, HIV Atlanta VA Cohort Study (HAVACS), Atlanta Veterans Affairs Medical Center, Decatur, GA, USA and Johann Wolfgang Goethe-Universität, HIVCENTER, Frankfurt, GermanySchool of Social and Community Medicine, University of Bristol, Bristol, UK, UPMC Univ Paris 06, UMR_S 943, F-75013, Paris, France; INSERM, UMR_S 943, F-75013, Paris, France; AP-HP, Hôpital Pitié-Salpétrière, Service des maladies infectieuses et tropicales, F-75013, Paris, France, Yale University School of Medicine, New Haven, CT, USA, VA Co

PMID: 23599235
PMCID: PMC4052127
DOI: 10.1093/ije/dyt010

Cohort profile: Antiretroviral Therapy Cohort Collaboration (ART-CC)

Margaret T May et al. Int J Epidemiol. 2014 Jun.

. 2014 Jun;43(3):691-702.

doi: 10.1093/ije/dyt010. Epub 2013 Apr 18.

Authors

Collaborators

Affiliations

¹ School of Social and Community Medicine, University of Bristol, Bristol, UK, UPMC Univ Paris 06, UMR_S 943, F-75013, Paris, France; INSERM, UMR_S 943, F-75013, Paris, France; AP-HP, Hôpital Pitié-Salpétrière, Service des maladies infectieuses et tropicales, F-75013, Paris, France, Yale University School of Medicine, New Haven, CT, USA, VA Connecticut Healthcare System, West Haven, CT, USA, Academisch Medisch Centrum bij de Universiteit van Amsterdam, Amsterdam, The Netherlands, University Hospital Lausanne, Lausanne, Switzerland, Clinic of Infectious Diseases & Tropical Medicine, San Paolo Hospital, University of Milan, Italy, Centre d'Estudis Epidemiològics sobre ITS/VIH/SIDA de Catalunya, Badalona, Spain, Division of Epidemiology and Population Health, British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada, Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada, Research Department of Infection and Population Health, UCL Medical School, London, UK, INSERM U.897, ISPED, Université Bordeaux, Bordeaux, France, Department of Internal Medicine University of Cologne, DE, Vanderbilt University School of Medicine, Nashville, TN, USA, National Epidemiology Center. Carlos III Health Institute, Madrid, Spain, Division of Infectious Diseases, University of Calgary, Calgary, Canada, University of Washington School of Medicine, Seattle, WA, USA, Division of Infectious Disease, Department of Medicine, University of Alabama, Birmingham, USA, HIV Atlanta VA Cohort Study (HAVACS), Atlanta Veterans Affairs Medical Center, Decatur, GA, USA and Johann Wolfgang Goethe-Universität, HIVCENTER, Frankfurt, Germany m.t.may@bristol.ac.uk.
² School of Social and Community Medicine, University of Bristol, Bristol, UK, UPMC Univ Paris 06, UMR_S 943, F-75013, Paris, France; INSERM, UMR_S 943, F-75013, Paris, France; AP-HP, Hôpital Pitié-Salpétrière, Service des maladies infectieuses et tropicales, F-75013, Paris, France, Yale University School of Medicine, New Haven, CT, USA, VA Connecticut Healthcare System, West Haven, CT, USA, Academisch Medisch Centrum bij de Universiteit van Amsterdam, Amsterdam, The Netherlands, University Hospital Lausanne, Lausanne, Switzerland, Clinic of Infectious Diseases & Tropical Medicine, San Paolo Hospital, University of Milan, Italy, Centre d'Estudis Epidemiològics sobre ITS/VIH/SIDA de Catalunya, Badalona, Spain, Division of Epidemiology and Population Health, British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada, Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada, Research Department of Infection and Population Health, UCL Medical School, London, UK, INSERM U.897, ISPED, Université Bordeaux, Bordeaux, France, Department of Internal Medicine University of Cologne, DE, Vanderbilt University School of Medicine, Nashville, TN, USA, National Epidemiology Center. Carlos III Health Institute, Madrid, Spain, Division of Infectious Diseases, University of Calgary, Calgary, Canada, University of Washington School of Medicine, Seattle, WA, USA, Division of Infectious Disease, Department of Medicine, University of Alabama, Birmingham, USA, HIV Atlanta VA Cohort Study (HAVACS), Atlanta Veterans Affairs Medical Center, Decatur, GA, USA and Johann Wolfgang Goethe-Universität, HIVCENTER, Frankfurt, Germany.
³ School of Social and Community Medicine, University of Bristol, Bristol, UK, UPMC Univ Paris 06, UMR_S 943, F-75013, Paris, France; INSERM, UMR_S 943, F-75013, Paris, France; AP-HP, Hôpital Pitié-Salpétrière, Service des maladies infectieuses et tropicales, F-75013, Paris, France, Yale University School of Medicine, New Haven, CT, USA, VA Connecticut Healthcare System, West Haven, CT, USA, Academisch Medisch Centrum bij de Universiteit van Amsterdam, Amsterdam, The Netherlands, University Hospital Lausanne, Lausanne, Switzerland, Clinic of Infectious Diseases & Tropical Medicine, San Paolo Hospital, University of Milan, Italy, Centre d'Estudis Epidemiològics sobre ITS/VIH/SIDA de Catalunya, Badalona, Spain, Division of Epidemiology and Population Health, British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada, Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada, Research Department of Infection and Population Health, UCL Medical School, London, UK, INSERM U.897, ISPED, Université Bordeaux, Bordeaux, France, Department of Internal Medicine University of Cologne, DE, Vanderbilt University School of Medicine, Nashville, TN, USA, National Epidemiology Center. Carlos III Health Institute, Madrid, Spain, Division of Infectious Diseases, University of Calgary, Calgary, Canada, University of Washington School of Medicine, Seattle, WA, USA, Division of Infectious Disease, Department of Medicine, University of Alabama, Birmingham, USA, HIV Atlanta VA Cohort Study (HAVACS), Atlanta Veterans Affairs Medical Center, Decatur, GA, USA and Johann Wolfgang Goethe-Universität, HIVCENTER, Frankfurt, GermanySchool of Social and Community Medicine, University of Bristol, Bristol, UK, UPMC Univ Paris 06, UMR_S 943, F-75013, Paris, France; INSERM, UMR_S 943, F-75013, Paris, France; AP-HP, Hôpital Pitié-Salpétrière, Service des maladies infectieuses et tropicales, F-75013, Paris, France, Yale University School of Medicine, New Haven, CT, USA, VA Co

PMID: 23599235
PMCID: PMC4052127
DOI: 10.1093/ije/dyt010

Abstract

The advent of effective combination antiretroviral therapy (ART) in 1996 resulted in fewer patients experiencing clinical events, so that some prognostic analyses of individual cohort studies of human immunodeficiency virus-infected individuals had low statistical power. Because of this, the Antiretroviral Therapy Cohort Collaboration (ART-CC) of HIV cohort studies in Europe and North America was established in 2000, with the aim of studying the prognosis for clinical events in acquired immune deficiency syndrome (AIDS) and the mortality of adult patients treated for HIV-1 infection. In 2002, the ART-CC collected data on more than 12,000 patients in 13 cohorts who had begun combination ART between 1995 and 2001. Subsequent updates took place in 2004, 2006, 2008, and 2010. The ART-CC data base now includes data on more than 70,000 patients participating in 19 cohorts who began treatment before the end of 2009. Data are collected on patient demographics (e.g. sex, age, assumed transmission group, race/ethnicity, geographical origin), HIV biomarkers (e.g. CD4 cell count, plasma viral load of HIV-1), ART regimen, dates and types of AIDS events, and dates and causes of death. In recent years, additional data on co-infections such as hepatitis C; risk factors such as smoking, alcohol and drug use; non-HIV biomarkers such as haemoglobin and liver enzymes; and adherence to ART have been collected whenever available. The data remain the property of the contributing cohorts, whose representatives manage the ART-CC via the steering committee of the Collaboration. External collaboration is welcomed. Details of contacts are given on the ART-CC website (www.art-cohort-collaboration.org).

Keywords: AIDS; HIV; antiretroviral therapy; cohort study; prognosis.

PubMed Disclaimer

Figures

**Figure 1**
Map of North American cohorts in the Antiretroviral Therapy Cohort Collaboration

**Figure 2**
Map of European cohorts in the Antiretroviral Therapy Cohort Collaboration EuroSIDA covers 31 European countries plus Israel and Argentina; the Infección por HIV y SIDA (PISCIS) Cohort includes two regions: Catalonia and the Balearic Islands

See this image and copyright information in PMC

References

1. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet. 1998;352:1725–30. - PubMed
1. Gill MJ, May M, Lewden C, Saag M, Mugavero MJ, Reiss P, et al. and the Antiretroviral Therapy Cohort Collaboration Causes of death in HIV-1 infected patients treated with antiretroviral therapy 1996–2006: collaborative analysis of 13 HIV cohorts. Clin Infect Dis. 2010;50:1387–96. - PMC - PubMed
1. May M, Hogg RS, Justice AC, Shepherd B, Costagliola D, Ledergerber B, et al. Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. Int J Epidemiol. 2012;41:1807–20. - PMC - PubMed
1. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360:119–29. - PubMed
1. Pozniak A, Gazzard B, Anderson J, Babiker A, Churchill D, Collins S, et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med. 2003;4(Suppl 1):1–41. - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Cohort profile: Antiretroviral Therapy Cohort Collaboration (ART-CC)

Collaborators

Affiliations

Cohort profile: Antiretroviral Therapy Cohort Collaboration (ART-CC)

Authors

Collaborators

Affiliations

Abstract

Figures

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Research Materials